Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Pancreas. 2022 Jan 1;51(1):e10–e12. doi: 10.1097/MPA.0000000000001955

TABLE 1.

Peak Bicarbonate Levels and Fluorescence Intensity for Biomarkers by Study Visit

Placebo (N = 2) Simvastatin (N = 6)
Baseline Month 3 Month 6 Baseline Month 3 Month 6
Peak bicarbonate level, mmol/L
 Mean (SD) 72.0 (9.9) 85.5 (14.8) 91.0 (15.6) 81.7 (23.4) 79.5 (17.9) 71.3 (18.0)
 Median (IQR) 72.0
(68.5–75.5)		 85.5
(80.3–90.8)		 91.0
(85.5–96.5)		 83.0
(69.5–89.8)		 82.5
(73.3–91.2)		 75.0
(72.0–79.5)
Least square mean* peak bicarbonate levels, mean (95% CI), mmol/L 49.5
(4.8–94.3)		 63.2
(28.7–97.7)		 75.6
(42.3–108.9)		 64.7
(38.9–90.6)		 63.3
(43.3–83.3)		 55.9
(36.6–75.2)
Least square mean† fluorescence intensity for biomarkers, mean (95% CI)
 Hepatocyte Growth Factor 7.13
(6.25–8.01)		 5.81
(5.13–6.48)		 5.99
(5.18–6.80)		 5.71
(5.20–6.22)		 5.81
(5.42–6.20)		 5.76
(5.29–6.23)
 Resistin 13.79
(12.99–14.60)		 12.85
(11.94–13.75)		 12.94
(11.83–14.05)		 12.39
(11.93–12.86)		 12.50
(11.97–13.02)		 12.45
(11.81–13.10)
 Fas Ligand 4.99
(4.67–5.30)		 5.08
(4.76–5.41)		 4.83
(4.48–5.18)		 4.83
(4.65–5.02)		 4.77
(4.59–4.96)		 4.82
(4.62–5.02)
*

Model fit with treatment, visit, and treatment x visit interaction

†

Mixed effects model with ID as random effect and treatment and visits as fixed effects

CI indicates confidence interval; IQR, interquartile range.